Remove 2007 Remove Licensing Remove Marketing
article thumbnail

VALILTRAMIPROSATE

New Drug Approvals

2007 ; Kocis et al., After tramiprosate failed in Phase 3, its maker, NeuroChem, marketed it as a nutritional supplement. Alzheon licensed ALZ-801 from NeuroChem and is developing it for Alzheimer’s disease. ALZ-801 is converted to homotaurine in vivo, but is more easily absorbed and lasts longer in the blood than tramiprosate.

article thumbnail

Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression

The Pharma Data

2007) Am J. . National Institute of Mental Health. Major Depression. Retrieved from [link]. World Health Organization. Fact Sheets: Depression, accessed November 23, 2020, [link]. Rush AJ, et al. Psychiatry 163:11, pp. 1905-1917 (STAR*D Study). Forward Looking Statements.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

The Pharma Data

months (Vermorken et al, JCO 2007). Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. The activity of cetuximab as a single agent in recurrent and/or metastatic SCCHN is limited, with a 12.6%

article thumbnail

Athersys Announces Three Appointments to Board of Directors

The Pharma Data

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. She has been a member of the board of directors and a member of the executive committee of the New York Biotechnology Association since 2007. She earned a BA from Durham University, U.K.,

article thumbnail

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

The Pharma Data

On February 26, 2021, the European Medicines Agency (EMA) accepted for review Pfizer’s Marketing Authorization Application (MAA) for the 20-valent pneumococcal conjugate vaccine candidate, as submitted for the prevention of invasive disease and pneumonia caused by S. Bacterial Meningitis in the United States, 1998–2007.

Vaccine 52
article thumbnail

Article FDA Thank You FDA unveils long-awaited Patient Medication Information proposed rule

Agency IQ

In 2007, the FDA held a public workshop to hear from the public about the Medication Guides system; per the agency , “the public testified that the Medication Guides distribution processes needed improvement” and that it should be “shorter and easier to read.”

FDA 40
article thumbnail

Analysis Chemical Thank You Highlights of the EPA’s Unified Agenda for Spring 2023

Agency IQ

For increased flexibility in bringing PIPs to market, a developer can also submit both. The Primary Copper Smelting area source NESHAP, subpart EEEEEE, was promulgated pursuant to section 112(d) of the CAA on January 23, 2007. This rule is the second of two rulemakings (Phase II) that EPA is undertaking to update its FOIA regulations.